文章核心观点 - 公司发布的最新Veeva Pulse Field Trends报告显示，同步销售和市场营销活动有助于改善生物制药公司与医疗保健专业人员（HCP）的互动效果，特别是在HCP时间有限的情况下，提供深入的科学信息可以加速治疗采用[1][2][3][4] 行业现状 - 65%的HCP互动未同步，导致治疗采用速度减慢[2][3] - HCP的时间和注意力减少，去年每位HCP的面对面会议减少了7%[2] 公司观点 - 公司认为，通过协调销售和市场营销活动，可以弥补面对面会议的减少，但目前大多数HCP互动仍未同步[2] - 公司副总裁Dan Rizzo表示，复杂的药物需要更有效的沟通方式，协调的销售和市场营销模型可以更有效地传递深入的科学信息[4] 数据支持 - 未同步的销售和市场营销活动未能优化HCP的有限时间[3] - 同步的面对面会议和数字接触点可以改善结果，例如，代表会议后10天内进行数字曝光，处方可能性增加30%，参加演讲节目后接触数字广告的HCP处方可能性增加25%，访问品牌网站后处方可能性增加60%[3] 报告介绍 - Veeva Pulse Field Trends报告分析了全球80%以上商业生物制药现场团队的超过6亿次HCP互动和活动，是该行业最大的HCP互动基准[4] - 报告通过Veeva CRM和Veeva数据产品中的实时交易数据，提供生命科学领域的互动活动视图，每季度由Veeva索引，帮助公司有效准确地基准测试性能，设定正确的可操作目标以实现持续增长和影响[4]

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Veeva Systems (VEEV) .Veeva currently has an average brokerage re ...

Veeva Systems (VEEV) closed the most recent trading day at $236.87, moving +0.8% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.1%. Meanwhile, the Dow experienced a rise of 0.69%, and the technology-dominated Nasdaq saw an increase of 0.06%.The the stock of provider of cloud-based software services for the life sciences industry has risen by 11.21% in the past month, leading the Computer and Technology sector's gain of 4.92% and the S&P 500's gain of 4. ...

Veeva Systems (VEEV) shares ended the last trading session 5.2% higher at $235. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.3% gain over the past four weeks.The sharp upsurge in VEEV shares can be attributed to positive market sentiment surrounding its strong recent financial performance. The company has shown impressive growth, with a year-to-date returns of 22%. Investors seem to be optimistic about Veeva S ...

文章核心观点 - 该合作有助于Veeva Systems拓展在医疗保健和临床试验领域的业务,利用Walgreens广泛的网络接触到更多样化的患者群体 [1][3][4] - 该合作有助于Veeva Systems提升其在数字健康解决方案领域的声誉和增长潜力 [4] Veeva Systems的数据云和临床平台表现 - Veeva Data Cloud提供一系列数据解决方案,整合并增强了生命科学行业的数据可访问性和洞见 [5] - Veeva Compass产品正在获得市场认可,为客户提供比传统替代品更完整和准确的数据 [6] - Veeva Link产品也取得了良好进展,客户数量超过100家 [7] - Veeva临床平台通过统一的数据源简化了临床试验流程,提高了运营效率和合规性 [8] - Veeva Site Connect和Veeva Clinical Database (CDB)等新产品为简化临床试验过程和提高试验速度效率做出了重大贡献 [9] Veeva Systems的其他合作伙伴关系 - 与Vita Global Sciences、Tigermed和Boehringer Ingelheim等公司的合作进一步巩固了Veeva在人类和动物健康领域的领导地位,提升了其作为综合解决方案提供商的声誉 [10][11][12] 同行公司表现 - Solventum Corporation专注于提供创新的医疗保健解决方案,在数据分析和临床试验管理方面不断增强能力 [13][14] - IQVIA Holdings拥有庞大的医疗保健信息资源,在生命科学领域占据有利地位,并推出了基于人工智能的新产品 [15][16][17]

文章核心观点 - Veeva Systems公司拥有强大的产品组合,预计未来几个季度将保持良好的增长势头[1][3] - 公司二季度财报表现出色,研发投入持续增加,为未来发展奠定基础[9] - 但运营成本上升仍是一个值得关注的问题[1][10] 公司概况 - Veeva Systems是一家提供云端软件应用和数据解决方案的公司,主要服务于生命科学行业[3] - 公司市值达343.7亿美元,预计未来5年将实现24.4%的增长,过去4个季度平均业绩超预期5.41%[3] 产品和业务发展 - 公司产品包括Veeva Vault、Veeva CRM、Veeva Network和Veeva OpenData等,不断推出新产品和功能[3][4][5][6][7] - 与沃尔格林建立长期合作关系,将进一步丰富Veeva Data Cloud产品[4] - 扩展Veeva Vault QMS功能,增加医疗器械领域的管理能力[5] - Vault CRM Service Center的发布实现了销售、营销、医疗和服务的整合[5] - Veeva Site Connect和Veeva Clinical Database在临床试验领域得到广泛应用[6][7] 财务表现 - 二季度毛利增长20.1%,毛利率扩大340个基点至74.8%[9] - 销售和营销费用同比增长4.7%,预计全年将持续上升[10] - 总运营费用同比增长6.9%[10] - 财年2025年每股收益预期为6.23美元,第三季度收入预期为6.837亿美元,同比增长10.9%[11]

DEERFIELD, Ill. and PLEASANTON, Calif., Oct. 24, 2024 /PRNewswire/ -- Walgreens (Nasdaq: WBA), an integrated healthcare, pharmacy, and retail leader, and Veeva Systems (NYSE: VEEV) a leading provider of software, data, and services for the life sciences industry, today announced a long-term partnership to help life sciences companies improve patient outcomes.The partnership enriches Veeva Data Cloud products and allows Walgreens to better serve life sciences through access to Veeva Data Cloud and Veeva Clin ...

PLEASANTON, Calif., Oct. 15, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will host its investor day virtually on Thursday, November 7, 2024. The event will begin at 1:30 p.m. PT and will conclude at approximately 3:30 p.m. PT. Veeva will broadcast the presentations live on the company's investor relations website, ir.veeva.com, where a link to the archived webcast will also be available after the event. Event: Veeva Systems 2024 Investor Day Date: Thursday, November 7, 2024 Time: 1:30 p.m. PT (4:30 p.m. ...

文章核心观点 - 公司最近一个交易日收盘价为210.13美元,较前一交易日上涨1.59% [1] - 公司过去一个月股价下跌7.62%,低于同期计算机和技术板块9.62%的涨幅以及标普500指数5.94%的涨幅 [1] - 分析师预计公司即将发布的财报中,每股收益将同比增长17.16%至1.57美元,收入将同比增长10.9%至6.83.69亿美元 [1] - 分析师预计公司全年每股收益和收入将分别同比增长28.72%和14.55%至6.23美元和27.1亿美元 [2] 公司相关 - 分析师对公司业务健康状况和盈利能力持乐观态度,体现在最近的估计修正中 [2] - 公司当前的市盈率为33.22倍,高于行业平均水平31.19倍 [3] - 公司的PEG率为1.36,低于行业平均水平2.03 [3] 行业相关 - 公司所在的互联网软件行业属于计算机和技术板块,目前行业排名在250多个行业中位于前28% [4] - 研究显示,排名靠前的行业相比排名靠后的行业平均表现要好2倍 [4]

Veeva Systems (VEEV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this provider of cloud-based software services for the life sciences industry have returned -4.3% over the past month versus the Zacks S&P 500 composite's +1.3% change. The Zacks Internet - Software industry, to which Veeva belongs, has gained 5.6% over this period. Now the key question is: Where cou ...